Patents by Inventor Christian Schôlz
Christian Schôlz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240161965Abstract: A transformer includes a sequence of insulating layers layered transversely to a common plane, and a plurality of at least two galvanically separated circuits. Each circuit has at least one conductor winding, and a common magnetic core only partially surrounding the layered sequence and acting on the number of the at least two circuits. Each conductor winding is disposed on a respective one of the layers and extends parallel to the common plane. The core optionally has a core portion extending parallel to the common plane and bounds the layered sequence to one side.Type: ApplicationFiled: March 10, 2022Publication date: May 16, 2024Inventors: Peter SCHOLZ, Yves HACKL, Christian REINHOLD
-
Patent number: 11967639Abstract: In accordance with an embodiment, a semiconductor device includes: an n-doped region disposed over an insulating layer; a p-doped region disposed over the insulating layer adjacent to the n-doped region, where an interface between the n-doped region and the p-doped region form a first diode junction; a plurality of segmented p-type anode regions disposed over the insulating layer, each of the plurality of segmented p-type anode regions being surrounded by the n-doped region, where a doping concentration of the plurality of segmented p-type anode regions is greater than a doping concentration of the p-doped region; and a plurality of segmented n-type cathode regions disposed over the insulating layer. Each of the plurality of segmented n-type cathode regions are surrounded by the p-doped region, where a doping concentration of the plurality of segmented n-type cathode regions is greater than a doping concentration of the n-doped region.Type: GrantFiled: January 26, 2022Date of Patent: April 23, 2024Assignee: Infineon Technologies AGInventors: Gernot Langguth, Anton Boehm, Christian Cornelius Russ, Mirko Scholz
-
Publication number: 20230120988Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.Type: ApplicationFiled: April 22, 2021Publication date: April 20, 2023Inventors: Frederik Baumkoetter, Juliane Benz, Markus Eckl, Peter Muench, Alexander Riedel, Christian Scholz
-
Patent number: 11567079Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: GrantFiled: September 20, 2019Date of Patent: January 31, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Christian Scholz, Peter Muench
-
Publication number: 20220220158Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ?-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.Type: ApplicationFiled: March 28, 2022Publication date: July 14, 2022Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
-
Patent number: 11319351Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.Type: GrantFiled: October 25, 2019Date of Patent: May 3, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
-
Patent number: 11312750Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.Type: GrantFiled: October 25, 2019Date of Patent: April 26, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
-
Publication number: 20210349090Abstract: The present description relates to a Corona antigen having a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits having the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using the Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.Type: ApplicationFiled: May 6, 2020Publication date: November 11, 2021Applicant: Roche Diagnostics Operations, Inc.Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
-
Publication number: 20210333277Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.Type: ApplicationFiled: April 23, 2020Publication date: October 28, 2021Applicant: Roche Diagnostics Operations, Inc.Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
-
Patent number: 10647765Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.Type: GrantFiled: March 16, 2018Date of Patent: May 12, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
-
Patent number: 10626177Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.Type: GrantFiled: August 3, 2017Date of Patent: April 21, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
-
Publication number: 20200048312Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
-
Publication number: 20200048313Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
-
Publication number: 20200033342Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: ApplicationFiled: September 20, 2019Publication date: January 30, 2020Inventors: Elke Faatz, Christian Scholz, Peter Muench
-
Publication number: 20190367601Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.Type: ApplicationFiled: March 16, 2018Publication date: December 5, 2019Inventors: Herbert ANDRES, David CASAGOLDA VALLRIBERA, Hartmut DUEFEL, Michael GERG, Christian SCHOLZ, Michael SCHRAEML
-
Patent number: 10466242Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: GrantFiled: August 25, 2016Date of Patent: November 5, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Christian Scholz, Peter Muench
-
Patent number: 10364290Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.Type: GrantFiled: August 3, 2017Date of Patent: July 30, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
-
Patent number: 10323107Abstract: Unsaturated compounds of formula (I): wherein: R1, R2, and R3 are each independently H or CH3; R4 is a linear or branched C1-C30-alkylene; R5 and R6 are each independently H, C1-C20-alkyl, C3-C15-cycloalkyl, aryl, —CH2—O—C1-C20-alkyl, or —CH2—O—C2-C20-alkenyl, where R5 and R6 may together form a C3-C6-alkylene; R7 is independently H,C1-C4-alkyl, or where R8 is C1-C22-alkyl or C2-C22-alkenyl; and n is an integer from 2 to 200. Mixtures and polymers including the unsaturated compounds of formula (I). A method for preparing polymers by free-radical polymerization of monomers including the unsaturated compounds of formula (I). A process for preparing polymers including polymer-analogous reactions. And polymers including compounds (I) as cement additives, grinding aids, hydraulic binder additives, concrete plasticizers, reactive plasticizers for preparing plastics, rubber, or latex, associative thickeners and antioxidants, or for preparing polyether siloxanes.Type: GrantFiled: October 30, 2014Date of Patent: June 18, 2019Assignee: BASF SEInventors: Sophie Maitro-Vogel, Martin Ernst, Christian Schade, Pavel Tuzina, Hoang Trang Tran-Thien, Eva-Maria Reis-Walther, Natalia Shabelina, Nina Susanne Hillesheim, Christian Scholz
-
Patent number: 10301383Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.Type: GrantFiled: January 22, 2016Date of Patent: May 28, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraemi
-
Patent number: 10197559Abstract: The invention concerns a fusion polypeptide including several molecules of folding helper polypeptides, including one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to the fusion polypeptide. The invention further concerns an immunoassay and the use of the fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising the fusion polypeptide.Type: GrantFiled: March 6, 2015Date of Patent: February 5, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Hartmut Duefel, Alexander Riedel, Peter Schaarschmidt, Urban Schmitt, Christian Scholz